Therapy for advanced stages of Parkinson's disease
- Authors: Karakulova Y.V.1, Golchenko E.A.2
-
Affiliations:
- E. A. Vagner Perm State Medical University
- V.I. Voinov Orenburg Regional Clinical Hospital
- Issue: Vol 41, No 4 (2024)
- Pages: 70-79
- Section: Review of literature
- URL: https://journals.rcsi.science/PMJ/article/view/267874
- DOI: https://doi.org/10.17816/pmj41470-79
- ID: 267874
Cite item
Full Text
Abstract
The search and analysis of data on treatment options of advanced stages of Parkinson's disease from various scientific sources on biomedical research PubMed in the Medline, Russian scientific electronic library CyberLeninka databases are summarized in the article. A comparison of data was performed to highlight the main directions of modern approaches to the treatment of advanced stages of Parkinson's disease. To treat the disease at a late stage with pronounced motor fluctuations in the form of “off” symptoms and painful dyskinesias during the “on” period, invasive and non-invasive high-tech methods of treatment are used. The most relevant method of treatment for Parkinson's disease in patients with a long history of the disease and side symptoms of traditional medicinal methods of correction are the use of Duodopa - levodopa/carbidopa intestinal gel (LCIG). It is important to note that the increased "on" period can allow people with advanced Parkinson's disease to raise motor activity, thereby improving their independence in daily activities from other people.
Full Text
##article.viewOnOriginalSite##About the authors
Yu. V. Karakulova
E. A. Vagner Perm State Medical University
Author for correspondence.
Email: julia.karakulova@mail.ru
ORCID iD: 0000-0002-7536-2060
DSc (Medicine), Professor, Head of the Department of Neurology and Medical Genetics
Russian Federation, PermE. A. Golchenko
V.I. Voinov Orenburg Regional Clinical Hospital
Email: julia.karakulova@mail.ru
ORCID iD: 0000-0003-3954-1405
Neurologist
Russian Federation, OrenburgReferences
- Рабаданова Е.А., Гельпей М.А., Гончарова З.А. Немоторные симптомы болезни Паркинсона, их структура и влияние на качество жизни пациентов. Практическая медицина 2015; 5 (90): 111–115 / Rabadanova E.A., Gelpei M.A., Goncharova Z.A. Non-motor symptoms of Parkinson's disease, their structure and impact on the quality of life of patients. Practical medicine 2015; 5 (90): 111–115 (in Russian).
- Титова Н.В., Чаудури К.Р. Немоторные симптомы болезни Паркинсона: подводная часть айсберга. Анналы неврологии 2017; 4: 1–14 / Titova N.V., Chauduri K.R. Non-motor symptoms of Parkinson's disease: the underwater part of the iceberg. Annals of Neurology 2017; 4: 1–144 (in Russian).
- Каракулова Ю.В., Гольченко Е.А., Яковлева Е.А. Взаимосвязь вегетативных и нервно-психических расстройств при болезни Паркинсона. Медицинский альманах 2022; 2 (21): 34–39 / Karakulova Yu.V., Golchenko E.A., Yakovleva E.A. Interconnection of vegetative and neuropsychiatric disorders in Parkinson's disease. Medical Almanac 2022; 2 (21): 34–39 (in Russian).
- Halli-Tierney A.D., Luker J., Carroll D.G. Parkinson Disease. Am Fam Physician. 2020; 102 (11): 679–691. PMID: 33252908.
- Antonini A., Odin P., Kleinman L., Skalicky A., Marshall M., Sail K., Onuk K. Implementing a Delphi Panel to Improve Understanding of Patient Characteristics of Advanced Parkinson’s Disease. Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders, San Diego, California, United States, June 14–18, 2015.
- Левин О.С., Федорова Н.В. Болезнь Паркинсона. М.: МЕДпрессинформ 2014; 384 / Levin O.S., Fedorova N.V. Parkinson's disease. Moscow: MEDpressinform 2014; 384 (in Russian).
- Fahn S., Poewe W. Levodopa: 50 years of a revolutionary drug for Parkinson disease. Movement Disorders 2015; 30 (1): 1–3.
- Резолюция заседания Совета экспертов «Развернутая стадия болезни Паркинсона. Возможности перехода на инвазивные методы лечения». Москва, 16 декабря 2016 г. Журнал неврологии и психиатрии им. C.C. Корсакова 2017; 117 (5): 117–118. doi: 10.17116/jnevro201711751117-118. – EDN YTANPN. / Resolution of the meeting of the Council of Experts "Advanced stage of Parkinson's disease. Opportunities for switching to invasive therapies". Moscow, December 16, 2016. S.S. Korsakov Journal of Neurology and Psychiatry 2017; 117 (5): 117–118. doi: 10.17116/jnevro201711751117-118. – EDN YTANPN (in Russian).
- Odin P., Chaudhuri K.R., Slevin J.T., Volkmann J., Dietrichs E., Martinez-Martin P., Krauss J.K., Henriksen T., Katzenschlager R., Antonini A., Rascol O., Poewe W. National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease: consensus from an international survey and discussion program. Parkinsonism & Related Disorders 2015; 21 (10): 1133–44.
- Rohani M., Fasano A. Focused ultrasound for essential tremor: review of the evidence and discussion of current hurdles. Tremor and Other Hyperkinetic Movements (New York, N.Y.) 2017; 7: 462.
- Галимова Р.М., Иллариошкин С.Н., Бузаев И.В., Качемаева О.В. Терапия двигательных нарушений методом фокусированного ультразвука под контролем магнитно-резонансной томографии: рекомендации для врачей-неврологов по отбору пациентов. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений 2020; 1: 9–15 / Galimova R.M., Illarioshkin S.N., Buzaev I.V., Kachemaeva O.V. Therapy of motor disorders by the method of focused ultrasound under the control of magnetic resonance imaging: recommendations for neurologists on the selection of patients. Bulletin of the National Society for the Study of Parkinson's Disease and Movement Disorders 2020; 1: 9–15 (in Russian).
- Бриль Е.В., Томский А.А., Гамалея А.А. и др. Электростимуляция субталамического ядра в лечении развернутых стадий болезни Паркинсона. Уральский медицинский журнал 2015; 2 (125): 14–19. EDN TQTZQJ / Bril E.V., Tomskiy A.A., Gamaleya A.A. i dr. Electrical stimulation of the subthalamic nucleus in the treatment of unfolded stages of Parkinson's disease. Ural Medical Journal 2015; 2 (125): 14–19. EDN TQTZQJ (in Russian).
- Magara A., Bühler R., Moser D., Kowalski M., Pourtehrani P., Jeanmonod D. First experience with MR-guided focused ultrasound in the treatment of Parkinson’s disease. Journal of Therapeutic Ultrasound 2014; 2: 11.
- Галимова Р.М., Набиуллина Д.И., Иллариошкин С.Н. и др. Первый опыт проведения таламотомии методом фокусированного ультразвука под контролем магнитно-резонансной томографии в России. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений 2022; 1: 3–8. doi: 10.24412/2226-079X-2022-12414. EDN SGQVEL / Galimova R.M., Nabiullina D.I., Illarioshkin S.N. i dr. The first experience of conducting thalamotomy by the method of focused ultrasound under the control of magnetic resonance imaging in Russia. Bulletin of the National Society for the Study of Parkinson's Disease and Movement Disorders 2022; 1: 3–8. doi: 10.24412/2226-079X-2022-12414. EDN SGQVEL (in Russian).
- Krishna V., Sammartino F., Rezai A. A review of the current therapies, challenges, and future directions of transcranial focused ultrasound technology: advances in diagnosis and treatment. JAMA Neurology 2018; 75 (2): 246–54.
- Alon Sinai, Yeshayahu Katz, Menashe Zaaroor, Olga Sandler, Ilana Schlesinger The Role of the Anesthesiologist during Magnetic ResonanceGuided Focused Ultrasound Thalamotomy for Tremor: A Single-Center Experience Hindawi Parkinson’s Disease. 2018; Article ID 9764807: 5.
- Ghanouni P., Pauly K.B., Elias W.J., Henderson J., Sheehan J., Monteith S., Wintermark M. Transcranial MRI-guided focused ultrasound: a review of the technologic and neurologic applications. AJR. American Journal of Roentgenology 2015; 205 (1): 150–9.
- Ахмадеева Г.Н., Галимова Р.М., Набиуллина Д.И. Лечение акинетико-ригидной формы болезни Паркинсона, осложненной развитием флуктуаций и дискинезий, методом деструкции с помощью фокусированного ультразвука. Нервные болезни 2022; 4: 26–30. doi: 10.24412/2226-0757-2022-12936. EDN MTLDXQ / Ahmadeeva G.N., Galimova R.M., Nabiullina D.I. Lechenie akinetiko-rigidnoj formy bolezni Parkinsona, oslozhnennoj razvitiem fluktuacij i diskinezij, metodom destrukcii s pomoshch'yu fokusirovannogo ul'trazvuka. Nervnye bolezni 2022; 4: 26–30. doi: 10.24412/2226-0757-2022-12936. EDN MTLDXQ (in Russian).
- Gallay M.N., Moser D., Magara A.E., Haufler F., Jeanmonod D. Bilateral MR-guided focused ultrasound pallidothalamic tractotomy for Parkinson’s disease with 1-year follow-up. Frontiers in Neurology 2021; 12: 601153.
- Ильина (Латыпова) Г.Р., Залялова З.А. Леводопа/карбидопа гель для интестинального введения в лечении развернутых стадий болезни Паркинсона: мировой и собственный опыт. Бюллетень Национального общества по изучению болезни Паркинсона и расстройств движений 2022; 2: 79–81. doi: 10.24412/2226-079X-2022-12440. EDN XOUWNZ / Ilyina (Latypova) G.R., Zalyalova Z.A. Levodopa/carbidopa gel for intestinal introduction in the treatment of advanced stages of Parkinson's disease: world and own experience. Bulletin of the National Society for the Study of Parkinson's Disease and Movement Disorders 2022; 2: 79–81. doi: 10.24412/2226-079X-2022-12440. EDN XOUWNZ (in Russian).
- Болезнь Паркинсона, вторичный паркинсонизм и другие заболевания, проявляющиеся синдромом паркинсонизма. Кодирование по Международной статистической классификации болезней и проблем, связанных со здоровьем: G20. G21.1. G21.2. G23.1-23.3. G23.8. Возрастная группа: Взрослые: клинические рекомендации. М. 2021 / Parkinson's disease, secondary parkinsonism and other diseases manifested by Parkinson's syndrome. Coding according to the International Statistical Classification of Diseases and Related Health Problems: G20. G21.1. G21.2. G23.1-23.3. G23.8. Age group: Adults: clinical guidelines. Moscow 2021 (in Russian).
- Рудакова А.В., Скоромец А.А., Тимофеева А.А. Фармакоэкономические аспекты применения интестинального геля, содержащего леводопу и карбидопу, при развернутых стадиях болезни Паркинсона. Медицинские технологии. Оценка и выбор 2016; 1 (23): 74–79. EDN VSLJTB / Rudakova A.V., Skoromets A.A., Timofeeva A.A. Pharmacoeconomic aspects of the use of intestinal gel, containing levodopa and carbidopa, in the developed stages of Parkinson's disease. Evaluation and selection 2016; 1 (23): 74–79. EDN VSLJTB (in Russian).
- Залялова З.А., Латыпова Г.Р. Маршрутизация пациентов с болезнью Паркинсона, получающих лечение посредством инфузий леводопа/карбидопа интестинального геля (Дуодопа). Болезнь Паркинсона и расстройства движений: руководство для врачей по материалам IV Национального конгресса по болезни Паркинсона и расстройствам движений (с международным участием). Под ред. С.Н. Иллариошкина, О.С. Левина. М. 2017; 195–6 / Zalyalova Z.A., Latypova G.R. Routing of patients with Parkinson's disease receiving treatment by infusions of levodopa/carbidopa intestinal gel (Duodopa). Parkinson's Disease and Movement Disorders. Guidelines for Physicians on the Proceedings of the IV National Congress on Parkinson's Disease and Movement Disorders (with international participation). Eds. S.N. Illarioshkin, O.S. Levin. Moscow 2017; 195–6 (in Russian).
- Скоромец А.А. и др. Леводопа-карбидопа интестинальный гель в терапии больных с развернутыми стадиями болезни Паркинсона: результаты 12-месячного открытого исследования. Журн. неврол. и психиатр. им. С.С. Корсакова 2017; 117 (2): 22–31/ Scoromec A.A. i dr. Levodopa-carbidopa intestinal gel in the therapy of patients with advanced stages of Parkinson's disease: results of a 12-month open-label study. Journe. Neurol. and a psychiatrist. named after S.S. Korsakov 2017; 117 (2): 22–31 (in Russian).
- Fasano A. et al. Concomitant medication usage with levodopa-carbidopa intestinal gel: results from the COSMOS study. Mov. Disord. 2021; 36 (8): 1853–62.
- Zhang X.R. et al. The advantages of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a systematic review. Drug Des. Devel. Ther. 2020; 14: 845–54
- Pahwa R., Aldred J., Merola A., Gupta N., Terasawa E., Garcia-Horton V., Steffen D.R., Kandukuri P.L., Bao Y., Ladhani O., Yan C.H., Chaudhari V., Isaacson S.H. Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson's disease: Post-hoc analyses from a large 54-week trial. Clin Park Relat Disord. 2022; 8: 100181. doi: 10.1016/j.prdoa.2022.100181. PMID: 36594071; PMCID: PMC9803946.
- Fasano A., Ricciardi L., Lena F., Bentivoglio A.R., Modugno N. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life. Eur Rev Med Pharmacol Sci. 2012; 16 (1): 79–89. PMID: 22338551.
- Ehlers C., Timpka J., Odin P., Honig H. Levodopa infusion in Parkinson's disease: Individual quality of life. Acta Neurol Scand. 2020; 142 (3): 248–254. doi: 10.1111/ane.13260. Epub 2020 May 22. PMID: 32383152.
- Fernandez H., Standaert D., Hauser R.A. et al. Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: Final 12-Month, Open-Label Results. Mov Disord. 2015; 30: 500–508.
- Catalán M.J., Escribano P.M., Alonso-Frech F. Dyskinesias in levodopa-carbidopa intestinal gel infusion era: New challenges, new features. Mov Disord. 2017; 32 (4): 624–625. doi: 10.1002/mds.26903. Epub 2017 Jan 24. PMID: 28116835.
- Regidor I., Santos-García D., Catalán M.I.J., Puente V., Valldeoriola F., Grandas F., Mir P., Parra J.C., Arbelo J.M. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. J Parkinsons Dis. 2019; 9 (1): 173–182. doi: 10.3233/JPD-181324. PMID: 30562907
- Chang F.C., Kwan V., van der Poorten D., Mahant N., Wolfe N., Ha A.D., Griffith J.M., Tsui D., Kim S.D., Fung V.S. Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease. J Clin Neurosci. 2016; 25: 41–5. doi: 10.1016/j.jocn.2015.05.059. Epub 2016 Jan 14. PMID: 26777085.
- Poewe W., Bergmann L., Kukreja P., Robieson W.Z., Antonini A. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety. J Parkinsons Dis. 2019; 9 (3): 531–541. doi: 10.3233/JPD-191605. PMID: 31282424; PMCID: PMC6700622.
- Fernandez H.H., Boyd J.T., Fung V.S.C., Lew M.F., Rodriguez R.L., Slevin J.T., Standaert D.G., Zadikoff C., Vanagunas A.D., Chatamra K., Eaton S., Facheris M.F., Hall C., Robieson W.Z., Benesh J., Espay A.J. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Mov Disord. 2018; 33 (6): 928–936. doi: 10.1002/mds.27338. Epub 2018 Mar 23. PMID: 29570853.
- Poewe W., Chaudhuri K.R., Bergmann L., Antonini A. Levodopa-carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. Neurodegener Dis Manag. 2019; 9 (1): 39–46. doi: 10.2217/nmt-2018-0034. Epub 2018 Dec 14. PMID: 30547712; PMCID: PMC6360350
Supplementary files
